A leading pharmaceutical company specialising in neurological treatments sought to enhance its portfolio with digital therapeutics (DTx), and approached m360 Research for competitive intelligence to identify a partner with innovative digital solutions to complement its pharmacotherapy offerings.
Navigating the DTx landscape presents several challenges. The market is fragmented, with numerous companies offering various digital solutions. Regulatory complexities, including evolving standards and regional variations, add another layer of difficulty.
By leveraging its expertise in secondary research and deep understanding of the life sciences industry, m360 Research conducted a thorough analysis of the DTx landscape. This involved identifying key players, their products, market positioning, and potential synergies with the client’s portfolio. Our expert team applied a multi-stage selection process, initially screening a large number of companies, narrowing down based on specific criteria, and finally selecting the best-fit candidates.
In the initial search, m360 Research identified 60+ digital products designed to treat conditions affecting the central nervous system (CNS), including neurodegenerative disorders, psychiatric disorders, and other neurological conditions. These products were either digital therapies or prescription digital therapeutics (PDTs). While related, they have crucial differences:
Not necessarily prescribed
They can be used by individuals without the need for a prescription
Evidence may vary
